FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015653345> ?p ?o ?g. }

• W3015653345 endingPage "113308" @default.
• W3015653345 startingPage "113308" @default.
• W3015653345 abstract "Stroke remains a leading cause of disability in the United States. Despite recent advances, interventions to reduce damage and enhance recovery after stroke are lacking. P2X4R, a receptor for adenosine triphosphate (ATP), regulates activation of myeloid immune cells (infiltrating monocytes/macrophages and brain-resident microglia) after stroke injury. However, over-stimulation of P2X4Rs due to excessive ATP release from dying or damaged neuronal cells can contribute to ischemic injury. Therefore, we pharmacologically inhibited P2X4R to limit the over-stimulated myeloid cell immune response and improve both acute and chronic stroke recovery. We subjected 8-12-week-old male and female wild type mice to a 60 min right middle cerebral artery occlusion (MCAo) followed by 3 or 30 days of reperfusion. We performed histological, RNA sequencing, behavioral (sensorimotor, anxiety, and depressive), and biochemical (Evans blue dye extravasation, western blot, quantitative PCR, and flow cytometry) analyses to determine the acute (3 days after MCAo) and chronic (30 days after MCAo) effects of P2X4R antagonist 5-BDBD (1 mg/kg P.O. daily x 3 days post 4 h of MCAo) treatment. 5-BDBD treatment significantly (p < .05) reduced infarct volume, neurological deficit (ND) score, levels of cytokine interleukin-1 beta (IL-1β) and blood brain barrier (BBB) permeability in the 3-day group. Chronically, 5-BDBD treatment also conferred progressive recovery (p < .05) of motor balance and coordination using a rotarod test, as well as reduced anxiety-like behavior over 30 days. Interestingly, depressive-type behavior was not observed in mice treated with 5-BDBD for 3 days. In addition, flow cytometric analysis revealed that 5-BDBD treatment decreased the total number of infiltrated leukocytes, and among those infiltrated leukocytes, pro-inflammatory cells of myeloid origin were specifically reduced. 5-BDBD treatment reduced the cell surface expression of P2X4R in flow cytometry-sorted monocytes and microglia without reducing the total P2X4R level in brain tissue. In summary, acute P2X4R inhibition protects against ischemic injury at both acute and chronic time-points after stroke. Reduced numbers of infiltrating pro-inflammatory myeloid cells, decreased surface P2X4R expression, and reduced BBB disruption are likely its mechanism of neuroprotection and neuro-rehabilitation." @default.
• W3015653345 created "2020-04-17" @default.
• W3015653345 creator A5010450034 @default.
• W3015653345 creator A5020152429 @default.
• W3015653345 creator A5022961880 @default.
• W3015653345 creator A5059025568 @default.
• W3015653345 creator A5060228083 @default.
• W3015653345 creator A5086537352 @default.
• W3015653345 date "2020-07-01" @default.
• W3015653345 modified "2023-10-14" @default.
• W3015653345 title "Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke" @default.
• W3015653345 cites W1890085699 @default.
• W3015653345 cites W1965597112 @default.
• W3015653345 cites W1977329281 @default.
• W3015653345 cites W1988889092 @default.
• W3015653345 cites W1996899635 @default.
• W3015653345 cites W2005130936 @default.
• W3015653345 cites W2007435066 @default.
• W3015653345 cites W2013821331 @default.
• W3015653345 cites W2026759178 @default.
• W3015653345 cites W2041034105 @default.
• W3015653345 cites W2065733359 @default.
• W3015653345 cites W2065737345 @default.
• W3015653345 cites W2067163875 @default.
• W3015653345 cites W2081522184 @default.
• W3015653345 cites W2082272773 @default.
• W3015653345 cites W2134412338 @default.
• W3015653345 cites W2144195410 @default.
• W3015653345 cites W2148914218 @default.
• W3015653345 cites W2160582541 @default.
• W3015653345 cites W2197491337 @default.
• W3015653345 cites W2343841798 @default.
• W3015653345 cites W2487049220 @default.
• W3015653345 cites W2512022815 @default.
• W3015653345 cites W2513944344 @default.
• W3015653345 cites W2539842921 @default.
• W3015653345 cites W2737588504 @default.
• W3015653345 cites W2767901905 @default.
• W3015653345 cites W2768102825 @default.
• W3015653345 cites W2897079566 @default.
• W3015653345 cites W2996608384 @default.
• W3015653345 doi "https://doi.org/10.1016/j.expneurol.2020.113308" @default.
• W3015653345 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7242087" @default.
• W3015653345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32289314" @default.
• W3015653345 hasPublicationYear "2020" @default.
• W3015653345 type Work @default.
• W3015653345 sameAs 3015653345 @default.
• W3015653345 citedByCount "50" @default.
• W3015653345 countsByYear W30156533452020 @default.
• W3015653345 countsByYear W30156533452021 @default.
• W3015653345 countsByYear W30156533452022 @default.
• W3015653345 countsByYear W30156533452023 @default.
• W3015653345 crossrefType "journal-article" @default.
• W3015653345 hasAuthorship W3015653345A5010450034 @default.
• W3015653345 hasAuthorship W3015653345A5020152429 @default.
• W3015653345 hasAuthorship W3015653345A5022961880 @default.
• W3015653345 hasAuthorship W3015653345A5059025568 @default.
• W3015653345 hasAuthorship W3015653345A5060228083 @default.
• W3015653345 hasAuthorship W3015653345A5086537352 @default.
• W3015653345 hasBestOaLocation W30156533452 @default.
• W3015653345 hasConcept C126322002 @default.
• W3015653345 hasConcept C127413603 @default.
• W3015653345 hasConcept C25498285 @default.
• W3015653345 hasConcept C2776914184 @default.
• W3015653345 hasConcept C2776991684 @default.
• W3015653345 hasConcept C2777649898 @default.
• W3015653345 hasConcept C2779830541 @default.
• W3015653345 hasConcept C2780645631 @default.
• W3015653345 hasConcept C42219234 @default.
• W3015653345 hasConcept C57306754 @default.
• W3015653345 hasConcept C71924100 @default.
• W3015653345 hasConcept C78519656 @default.
• W3015653345 hasConcept C87753298 @default.
• W3015653345 hasConcept C98274493 @default.
• W3015653345 hasConceptScore W3015653345C126322002 @default.
• W3015653345 hasConceptScore W3015653345C127413603 @default.
• W3015653345 hasConceptScore W3015653345C25498285 @default.
• W3015653345 hasConceptScore W3015653345C2776914184 @default.
• W3015653345 hasConceptScore W3015653345C2776991684 @default.
• W3015653345 hasConceptScore W3015653345C2777649898 @default.
• W3015653345 hasConceptScore W3015653345C2779830541 @default.
• W3015653345 hasConceptScore W3015653345C2780645631 @default.
• W3015653345 hasConceptScore W3015653345C42219234 @default.
• W3015653345 hasConceptScore W3015653345C57306754 @default.
• W3015653345 hasConceptScore W3015653345C71924100 @default.
• W3015653345 hasConceptScore W3015653345C78519656 @default.
• W3015653345 hasConceptScore W3015653345C87753298 @default.
• W3015653345 hasConceptScore W3015653345C98274493 @default.
• W3015653345 hasFunder F4320332161 @default.
• W3015653345 hasLocation W30156533451 @default.
• W3015653345 hasLocation W30156533452 @default.
• W3015653345 hasLocation W30156533453 @default.
• W3015653345 hasOpenAccess W3015653345 @default.
• W3015653345 hasPrimaryLocation W30156533451 @default.
• W3015653345 hasRelatedWork W2022779476 @default.
• W3015653345 hasRelatedWork W2060298694 @default.
• W3015653345 hasRelatedWork W2111623241 @default.
• W3015653345 hasRelatedWork W2803817550 @default.

• next